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U.S. Public Health Service Guidelines for Testing and
Counseling Blood and Plasma Donors for Human
Immunodeficiency Virus Type 1 Antigen
Summary
The Public Health Service (PHS) has recommended a multifaceted approach
to blood safety in the United States that includes stringent donor selection prac-
tices and the use of screening tests. Blood donations in the United States have
been screened for antibody to human immunodeficiency virus type 1 (HIV-1)
since March 1985 and type 2 (HIV-2) since June 1992. An estimated one in
450,000 to one in 660,000 donations per year (i.e.,18–27 donations) are infectious
for HIV but are not detected by currently available screening tests. Because
maintaining a safe blood supply is a public health priority, the Food and Drug
Administration (FDA) recommended in August 1995 that all donated blood and
plasma also be screened for HIV-1 p24 antigen, effective within 3 months of li-
censure of a test labeled for such use. Donor screening for p24 antigen is
expected to reduce the number of otherwise undetected infectious donations by
approximately 25% per year. 
Routine testing for p24 antigen in settings other than blood and plasma cen-
ters as a method for diagnosing HIV infection is discouraged because the
estimated average time from detection of  p24 antigen to detection of HIV anti-
body is 6 days, and not all recently infected persons have detectable levels of
p24 antigen. Among children ≥18 months of age and adults, diagnostic testing
for HIV infection, including confirmatory testing, should routinely be performed
with FDA-licensed assays for antibodies to HIV-1; p24-antigen tests alone should
not be used for diagnosing HIV infection.
This report provides PHS guidelines for a) interpreting p24-antigen–assay
results, b) counseling and follow-up of blood donors who have positive or inde-
terminate p24-antigen–test results, and c) using p24-antigen testing in settings
other than blood banks.
INTRODUCTION
In the United States, the implementation of antibody testing in 1985 of all donated
blood for human immunodeficiency virus type 1 (HIV-1) resulted in a substantial de-
crease in the transmission of HIV through blood transfusions (1,2 ). To further
decrease the risk for transmission of HIV by transfusion, the testing of all blood
donations with a combination antibody test for HIV-1 and HIV type-2 (HIV-2) was im-
plemented by June 1992. 
The risk for HIV transmission by transfusion of screened blood is minimal. Nearly
all cases of transfusion-associated HIV transmission are now caused by blood
donated during the infectious window period (i.e., when recently infected donors
are infectious but have not yet developed detectable levels of HIV antibody). When
whole-virus–lysate enzyme immunosorbent assays (EIAs) were used to screen blood
donations from 1985 through 1990, the average length of the window period was
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45 days (95% confidence interval [CI]=34–55 days) (3 ). The average window period of
the most sensitive contemporary recombinant protein-based EIA for HIV-1 and HIV-2
antibodies is now 20 days less (4 ), yielding an average infectious window period of
25 days (95% CI=9–41 days) (5 ). 
The increased sensitivity of contemporary HIV-antibody EIAs, improved donor in-
terviewing about behaviors associated with risk for HIV infection, and deferral of
donors who test positive for HIV, hepatitis, human T-cell leukemia virus type 1 (HTLV-I),
or syphilis have considerably improved the safety of the U.S. blood supply. In 1993,
only approximately six per 100,000 blood donations collected by the American Red
Cross tested positive for HIV antibody (6 ). In addition, only an estimated one in
450,000 to one in 660,000 donations per year (i.e., 18–27 donations) were infectious for
HIV but were not detected by current screening tests (5 ).
During the acute period of infection, tests for p24 antigen can detect HIV infection
earlier than antibody tests. P24 antigen, the core structural protein of HIV, is detectable
2–3 weeks after HIV infection during the initial burst of virus replication associated
with high levels of viremia (7,8 ). During this time, the blood of infected persons is
highly infectious, and tests for p24 antigen are usually positive (9–11 ). On average,
p24 antigen is detected an estimated 6 days before antibody tests become positive
(4,9 ). When antibodies to HIV become detectable, p24 antigen is often no longer de-
tectable because of antigen-antibody complexing and viral clearance (9–11 ). 
In August 1995, the Food and Drug Administration (FDA) recommended that all
blood and plasma donations be screened for p24 antigen, effective within 3 months of
licensure of a test labeled for such use (12 ). FDA recommended p24 screening as an
additional safety measure because a) recent studies indicated that p24 screening re-
duces the infectious window period (4 ), b) implementation of p24-antigen testing had
become logistically feasible for mass screening, and c) such testing would reduce the
risk for HIV infection for persons who receive donated blood or blood products.
Among the 12 million annual blood donations in the United States, p24-antigen
screening is expected to detect four to six infectious donations that would not be iden-
tified by other screening tests. If each of these units were divided into an average of
1.8 blood components (13 ), antigen testing would result in removal of an estimated
seven to 11 infectious components each year that would otherwise be available for
transfusion. FDA regards donor screening for p24 antigen as an interim measure
pending the availability of technology that would further reduce the risk for HIV trans-
mission from blood donated during the infectious window period.
This report provides guidelines for a) interpreting p24-antigen–assay results,
b) counseling and follow-up of blood and plasma donors who have positive or inde-
terminate antigen-test results, and c) using p24-antigen testing in settings other than
blood banks. These guidelines may be modified when additional information concern-
ing antigen testing under mass screening conditions is collected and analyzed. 
P24-ANTIGEN–TEST ALGORITHM
AND INTERPRETATION OF TEST RESULTS 
The p24-antigen screening assay is an EIA performed on serum or plasma.
If the first screening test is nonreactive, the test result is reported as negative
(see Definitions used in interpreting HIV-1 p24-antigen tests according to FDA
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recommendations). If the first screening test is reactive, the p24 EIA is repeated in
duplicate. If both duplicate tests are nonreactive, the test result is reported as nega-
tive. If at least one of the repeated p24 EIA tests is reactive, the test is considered
repeatedly reactive; the donation is then discarded, the donor is deferred from donat-
ing blood, and a more specific assay (the neutralization assay) is performed to verify
the presence of p24 antigen. The neutralization assay should be performed before
informing donors of test results. As specified by FDA (12 ), donations collected within
3 months of a repeatedly reactive p24-antigen test (regardless of neutralization-assay
results) should be quarantined pending results of repeat donor testing for antigen and
antibody to HIV. Sample storage requirements and time restrictions specified in the
test kit package insert should be closely followed to prevent sample deterioration, and
thus, invalid test results. FDA recommends that units of whole blood, blood compo-
nents, source leukocytes, and source plasma obtained from donors whose blood
samples are repeatedly reactive on p24-antigen screening tests be destroyed or quar-
antined and not used for transfusion or for manufacturing into injectable products.
Available data indicate that the p24-antigen assay is sensitive and specific. The
specificity of the p24-antigen test was calculated by two test-kit manufacturers to be
99.95% and 99.93% (Table 1) (14 ). Additionally, in one study of 514,000 donations,
225 were repeatedly reactive on the screening test. Of these donations, neutralization
tests were negative for 220 (98%). Five (2%) donations were negative on neutralization
tests and had detectable HIV antibodies. Testing by the polymerase chain reaction
(PCR) for HIV DNA and RNA was performed on 120 of these non-neutralizing blood
donations, all of which were negative for HIV. Follow-up samples were obtained
from 79 of these donors, all of which were negative for HIV-1 antibody (15 ). In a pro-
spective study conducted from September 1993 through September 1995, a total of
• Initially reactive Initial p24 EIA test is reactive.
• Repeatedly reactive One or both duplicate p24 EIA retests is (are) reactive.
• Negative Initial p24 EIA test is not reactive; or, initial p24 EIA test
is reactive and both duplicate p24 EIA retests are not
reactive.
• Positive P24 EIA test is repeatedly reactive and the neutral-
ization test is positive (i.e, neutralizing).
• Indeterminate P24 EIA test is repeatedly reactive and the neutral-
ization test is either negative (i.e., non-neutralizing) or
invalid.
Definitions used in interpreting HIV-1 p24-antigen tests according to FDA
recommendations
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305,989 donations were tested for p24 antigen; three donors had both repeatedly re-
active p24-antigen EIA screening-test results and positive neutralization results (two
of whom were also HIV-antibody positive), and 223 donors had repeatedly reactive
p24-antigen EIA screening-test results and negative neutralization results. Of those
donors who had negative neutralization results, 81 later returned to donate blood
again. Sixty-five of these donors had negative test results for HIV-1/HIV-2 antibody and
for antigen EIA and neutralization. However, 16 donors who were HIV-1/HIV-2 antibody
negative on subsequent donations continued to have repeatedly reactive p24-antigen
EIA screening tests that did not neutralize (16 ).
A recent study of 51 seroconversion panels has yielded an estimate of clinical sen-
sitivity of the p24-antigen screening test in detecting blood donated during the
infectious window period. An analysis of 69 preseroconversion samples that were
positive for HIV-1 RNA by PCR demonstrated that the antigen test was reactive
for 51 (74%) of those samples (M.P. Busch, personal communication, 1995). To assess
sensitivity of the neutralization test, two antigen-test–kit manufacturers also per-
formed neutralization testing on samples of blood from persons seroconverting
to HIV. One manufacturer tested 102 repeatedly reactive specimens from 30 serocon-
verting plasma donors; 100% were positive on the neutralization assay. Similarly, a
second manufacturer found that all 52 repeatedly reactive specimens from 25 sero-
converting plasma donors were positive on the neutralization test (14 ).
DONOR COUNSELING, FOLLOW-UP, AND DEFERRAL
Counseling blood and plasma donors who have positive or indeterminate HIV-test
results is an essential adjunct to HIV testing. Counseling in the blood-bank setting a)
provides information about follow-up diagnostic evaluation and available medical,
preventive, and psychosocial services and b) assists infected persons in preventing
transmission to others. HIV counseling should be conducted in accordance with PHS
standards and guidelines (17,18 ). 














A Blood donors 301,699 1,348 (0.45) 144 (0.05) 3† ( 2.10)
B Blood and
plasma donors  10,270    47 (0.46)   8 (0.08) 1§ (12.50)
*Percentage of specimens that were repeatedly reactive.
†Two of three specimens were also antibody positive. The third specimen was from a donor
who subsequently showed no other evidence of HIV infection. The specificity of Manufacturer
A’s antigen assay is approximately 99.95% (301,555 per 301,697) based on a) an assumed zero
prevalence of HIV-1 p24 antigen in random blood donors who have no other evidence of HIV-1
infection and b) additional testing using the neutralization test and Western blot analysis for
HIV-1 antibodies.
§The repeatedly reactive specimen was confirmed as being HIV-1 p24-antigen positive; the
donor subsequently seroconverted to antibodies to HIV-1. When the HIV-1 p24-antigen–positive
donor was removed from the calculation, the specificity of Manufacturer B’s test was
99.93% (10,262 per 10,269; 95% confidence interval=99.86%–99.97%).
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PHS guidelines for notification and counseling of donors who have repeatedly
reactive antigen-test results are based on available data. These guidelines may be
modified after the collection and analysis of additional information concerning anti-
gen testing under mass screening conditions. 
Donors Who Have Positive P24-Antigen–Test Results
Donors whose HIV-antibody–test results are negative, but whose screening-test re-
sults for HIV antigen are repeatedly reactive and neutralization-assay results are
positive, should be counseled that they are probably infected with HIV (Figure 1).
Donors who have such test results should be notified promptly after a positive neu-
tralization test. Prompt notification is important because persons who are newly
infected with HIV and do not have HIV antibodies often have high viral titers and may
be at high risk for transmitting HIV infection (7 ). According to FDA recommendations,
donors who have repeatedly reactive and neutralizing p24-antigen tests should be ad-
vised that they are permanently deferred from future blood and plasma donation.
Donors who have repeatedly reactive EIA and neutralizing HIV antigen tests should
have their results confirmed by follow-up antibody testing; diagnosis of HIV infection
should not be made on the basis of p24-antigen–test results alone. Arrangements for
follow-up antibody testing should be incorporated into routine counseling. Because
the time between detection of antigen and antibody is estimated to be an average of
6 days, donors who have positive p24-antigen–test results can be offered repeat anti-
gen and antibody testing at any follow-up visit. If repeat antigen tests remain reactive
and antibody tests remain negative, antibody testing should be repeated after a mini-
mum of 8 weeks to allow time for antibodies to develop. Pending repeat testing to
confirm the initial positive antigen-test result, strategies to reduce transmission
should be implemented immediately by the donor (e.g., abstaining from sexual inter-
course and using condoms consistently and correctly). If follow-up antibody tests are
positive—thus confirming HIV infection—infected persons should be referred for
medical care; sex and needle-sharing partners of such persons should be advised to
seek HIV testing at clinical sites.
Some donors repeatedly have positive p24-antigen and negative HIV-antibody–test
results, although such an occurrence is unusual. If after 8 weeks such persons still
have negative antibody-test results, they should be referred for further medical evalu-
ation, including determining CD4+ T-lymphocyte cell count or percentage. Testing for
HIV by PCR or culture also may be helpful in determining HIV status; however, neither
test is licensed for diagnosis of HIV infection.
Donors Who Have Repeatedly Reactive P24-Antigen
Screening-Test Results but Negative or Invalid
Neutralization-Test Results
In the blood- and plasma-donor population, which has a low prevalence of HIV in-
fection, most repeatedly reactive p24-antigen screening-test results are expected to be
false-positive reactions. Donors who have repeatedly reactive p24-antigen screening
tests but have negative neutralization and HIV-antibody tests are probably not infected
with HIV. Donors who have negative neutralization results should be counseled that
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Repeat p24-antigen EIA test in duplicate
If screening p24 EIA 
reactive after 8 weeks, 
permanently defer 
donor
If screening p24 EIA 
negative after 8 weeks, 
reinstate donor
Follow-up  and retest for HIV 
antigen and HIV antibody at any 
time; however, if antigen tests 
remain reactive and antibody 
tests remain negative, retest 
after 8 weeks
Follow-up  and retest for HIV 
antigen and HIV antibody at any 
time; however, if antigen tests 
remain reactive and antibody 
tests remain negative, retest 
after 8 weeks




Counsel donor probably 
not infected but should 










Initial p24-antigen test result
Nonreactive Reactive
Test interpreted
as negative Both tests nonreactive One or both tests reactive
Process and use 
blood donation
Destroy blood donation
Perform p24-antigen neutralization test
FIGURE 1. Algorithm for p24-antigen testing, donor notification and counseling, unit
disposition, follow-up evaluation, and deferral of blood and plasma donors who have
negative HIV-antibody–test results
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their antigen screening tests were reactive but that their supplementary tests were
negative, which likely represents a false-positive test. Although donors who have
negative neutralization results should be reassured that their test result probably does
not represent infection, they should be counseled to take HIV risk-reduction precau-
tions until repeat testing has confirmed their HIV-infection status. 
An invalid neutralization result occurs when a sample is repeatedly reactive in the
initial screening test, but in the neutralization assay, the neutralized sample and
unneutralized control both fall below the cutoff level. Most frequently, invalid results
occur when a screening-test value is low or borderline reactive in an uninfected per-
son; however, invalid results can also occur when a screening-test value is low or
borderline reactive in an infected person (15 ). An invalid result may also be the result
of sample deterioration or antigen-antibody complex formation during storage.
Donors who have invalid neutralization results should be counseled that their antigen
screening tests were reactive but their supplementary tests were inconclusive
because the neutralization-test results were invalid. These donors are probably not
infected with HIV, but infection cannot be excluded. Donors who have invalid
neutralization-test results should be counseled to take HIV risk-reduction precautions
until their HIV-infection status is confirmed. Retesting a fresh sample may clarify the
result.
To exclude HIV infection, donors who have repeatedly reactive p24-antigen
screening-test results, invalid or negative neutralization-test results, and negative HIV-
antibody–test results can be offered repeat antigen and antibody testing at any
follow-up visit. Negative antigen- and antibody-test results at the time of follow-up
indicate the donor was not infected with HIV at the time of the initial test. For donor
reentry purposes, or for diagnostic purposes among donors who continue to have
reactive antigen screening-test results and negative antibody-test results, repeat anti-
gen and antibody testing should be performed a minimum of 8 weeks after the initial
repeatedly reactive antigen screening test. Negative antigen and antibody tests per-
formed ≥8 weeks after the initial repeatedly reactive antigen screening tests indicate
the donor was not infected with HIV at the time of the initial test. If the donor’s screen-
ing antigen test remains repeatedly reactive, neutralization test remains negative,
and HIV-antibody tests are negative or indeterminate, the donor is probably not
infected with HIV. Further follow-up and additional tests (i.e., CD4+ T-lymphocyte cell
count or percentage, HIV PCR, and culture) may clarify infection status, although these
tests are not licensed for diagnosis of HIV infection.
FDA recommendations indicate that donors whose blood samples are repeatedly
reactive by the p24 screening test and negative or invalid on the neutralization test
should be temporarily deferred from donating blood or plasma for a minimum of 8
weeks. These persons should be counseled that donor deferral does not indicate in-
fection, because the screening test on which the deferral was based was most likely a
false-positive result. If, after 8 weeks, samples from such donors test negative by
screening tests for p24 antigen and antibodies to HIV, the donors are not infected and
can be reinstated as blood or plasma donors. However, if, after 8 weeks, samples
test repeatedly reactive on the screening test for HIV antigen or are positive for
antibody, the donors should be permanently deferred from donating blood or
plasma—regardless of HIV-antigen neutralization-test results.
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IMPLICATIONS FOR OTHER HIV TEST SITES
Initiation of p24-antigen screening of the blood supply may motivate some persons
who are at high risk for HIV infection to donate blood to determine HIV status. Such an
unintended inducement could offset the benefits of p24-antigen screening (19 ). Since
1983, PHS has discouraged persons at high risk for HIV infection from donating blood
(20 ). Such persons should be discouraged from donating blood and plasma and en-
couraged to be tested for HIV antibody at other sites.
Initiation of routine testing for p24 antigen in publicly funded HIV counseling
and testing sites, physicians’ offices, or other nonblood-bank settings is not recom-
mended. Few additional infected persons would be identified by routine antigen
testing in such settings, because the estimated average time from detection of p24
antigen to detection of antibody is only 6 days. In addition, recently infected persons
may not have detectable levels of p24 antigen. However, antigen testing may be ap-
propriate in certain circumstances, such as diagnosis of perinatally exposed children
(21,22 ). Diagnostic testing for HIV infection in children ≥18 months of age and adults
should routinely consist of an HIV-1–antibody screening test and Western blot or im-
munofluorescent assay for confirmation of antibodies to HIV-1.
CONCLUSIONS
PHS is committed to maintaining a safe blood supply. To further promote this goal,
FDA has recommended that all blood and plasma donations be screened with tests for
HIV-1 p24 antigen because these test results frequently become positive before assays
for HIV antibodies. Screening blood donors for p24 antigen is expected to remove four
to six infectious donations from the blood supply each year that would not be re-
moved by other screening tests.
After implementation of p24-antigen screening, CDC will collaborate with blood-
and plasma-collection agencies to evaluate the sensitivity, specificity, and positive
predictive value of the p24-antigen test. As a result, the p24-antigen testing algorithm
and counseling guidelines may be modified after additional data are collected and
analyzed.
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